Jie Zhang

D. Tan, Geoffrey Liu, Zheng-Yi Zhou, 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

The association of chemotherapy versus hormonal therapy and health outcomes among patients with hormone receptor-positive, HER2−negative metastatic breast cancer: experience from the patient perspective

G. Jerusalem, Shaloo Gupta, Jie Zhang, 2014, Expert review of pharmacoeconomics & outcomes research.

A Review of Two Regulatory Approved Anti-CD19 CAR T-Cell Therapies in Diffuse Large B-Cell Lymphoma: Why Are Indirect Treatment Comparisons Not Feasible?

Junlong Li, E. Wu, J. Signorovitch, 2020, Advances in Therapy.

Lifetime Costs for Treated Follicular Lymphoma Patients in the US

T. Delea, R. Maziarz, Q. Ma, 2021, PharmacoEconomics.

Disease management patterns for postmenopausal women in Europe with hormone-receptor-positive, human epidermal growth factor receptor-2 negative advanced breast cancer

P. Neven, F. André, G. Jerusalem, 2014, Current medical research and opinion.

Real-world patterns of endocrine therapy for metastatic hormone-receptor-positive (HR+)/human epidermal growth factor receptor-2-negative (HER2−) breast cancer patients in the United States: 2002–2012

J. Signorovitch, E. Swallow, D. Thomason, 2014, Current medical research and opinion.

Variation in adherence with Global Initiative for Chronic Obstructive Lung Disease (GOLD) drug therapy guidelines: a retrospective actuarial claims data analysis

K. Iwasaki, K. Fitch, B. Pyenson, 2011, Current medical research and opinion.

LC‐MS Bioanalysis of Steroids

F. Stanczyk, Jie Zhang, 2013 .

Economic Burden of Neurologic Toxicities Associated with Treatment of Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma in the United States.

M. Broder, E. Chang, L. Eldjerou, 2020, American health & drug benefits.

Patient-reported physical, emotional, and social functioning in advanced breast cancer: Insights from BOLERO-2.

P. Neven, G. Hortobagyi, J. Baselga, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Comparative efficacy of everolimus versus fulvestrant for hormone-receptor–positive (HR+) advanced breast cancer (ABC) following progression/recurrence after first-line treatment: A network meta-analysis.

S. Duffy, G. Jerusalem, T. Bachelot, 2013 .

Association between consistent omalizumab treatment and asthma control.

P. Lefebvre, Jie Zhang, M. Lafeuille, 2013, The journal of allergy and clinical immunology. In practice.

Outcome of Multimodality Treatment for 188 Cases of Type B3 Thymoma

W. Fang, Jie Zhang, S. Fu, 2013, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

CAR-T therapy and historical trends in effectiveness and cost-effectiveness of oncology treatments.

Y. Hao, J. Baumgardner, D. Lakdawalla, 2020, Journal of comparative effectiveness research.

Integrating expert opinion with clinical trial data to extrapolate long-term survival: a case study of CAR-T therapy for children and young adults with relapsed or refractory acute lymphoblastic leukemia

J. Jansen, K. Batt, D. Ayers, 2019, BMC Medical Research Methodology.

Tisagenlecleucel versus historical standard therapies for pediatric relapsed/refractory acute lymphoblastic leukemia.

Q. Ma, Jie Zhang, Amber Martin, 2020, Journal of comparative effectiveness research.

Patient-reported long-term quality of life after tisagenlecleucel in relapsed/refractory diffuse large B-cell lymphoma.

G. Salles, U. Jaeger, H. Holte, 2020, Blood advances.

Patient-reported quality of life after tisagenlecleucel infusion in children and young adults with relapsed or refractory B-cell acute lymphoblastic leukaemia: a global, single-arm, phase 2 trial.

K. Davis, S. Rives, A. Baruchel, 2019, The Lancet. Oncology.

The Disability Burden of COPD

J. Romley, D. Goldman, Michael R. Eber, 2012, COPD.

Pulmonary medication adherence and health-care use in cystic fibrosis.

K. Riekert, A. Quittner, J. Signorovitch, 2014, Chest.

Characteristics and outcomes of ALK+ non‐small cell lung cancer patients in Korea

M. Ahn, Keunchil Park, S. Lim, 2017, Asia-Pacific journal of clinical oncology.

Commercialising CAR-T Therapies

E. Ostuni, M. Robson, Simona Paratore, 2020 .

Is time to progression associated with post-progression survival in previously treated metastatic non-small cell lung cancer with BRAF V600E mutation? A secondary analysis of phase II clinical trial data

Junlong Li, Jing Zhao, J. Signorovitch, 2018, BMJ Open.

Economic Analysis of Alternative Strategies for Detection of ALK Rearrangements in Non Small Cell Lung Cancer

P. Koduru, F. Fogt, Jie Zhang, 2016, Diagnostics.

ALK rearrangement testing and treatment patterns for patients with ALK-positive non-small cell lung cancer.

H. Wakelee, E. Wu, A. Macalalad, 2015, Cancer epidemiology.

Evaluating cost benefits of combination therapies for advanced melanoma

C. Blanchette, Jie Zhang, I. Jensen, 2016, Drugs in context.

A Continuous Publication, Open Access, Peer-reviewed Journal

C. Blanchette, Jie Zhang, I. Jensen, 2022 .

The phenotypes of germinal center B-cell-like ( GCB ) and non-GCB failed to predict the survival of patients with diffuse large B-cell lymphoma in the rituximab era

Ping Chen, Jie Zhang, Jun Zhang, 2017 .

Predicting Real-World Effectiveness of Cancer Therapies Using Overall Survival and Progression-Free Survival from Clinical Trials: Empirical Evidence for the ASCO Value Framework.

R. Brookmeyer, R. Figlin, J. Shafrin, 2017, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

The Trade-off Between Speed and Safety in Drug Approvals.

A. Jena, D. Lakdawalla, Jie Zhang, 2017, JAMA oncology.

Modeling the effects of omalizumab over 5 years among patients with moderate-to-severe persistent allergic asthma

P. Alperin, A. Schlender, Jie Zhang, 2010, Current medical research and opinion.

Cost associated with hematopoietic stem cell transplantation: a retrospective claims data analysis in Germany.

M. Lehne, Jie Zhang, L. Hickstein, 2019, Journal of comparative effectiveness research.

Inhaled corticosteroid use in patients with chronic obstructive pulmonary disease and the risk of pneumonia: a retrospective claims data analysis

B. Yawn, Yunfeng Li, S. Arcona, 2013, International journal of chronic obstructive pulmonary disease.

Efficacy of indacaterol 75 μg versus fixed-dose combinations of formoterol-budesonide or salmeterol-fluticasone for COPD: a network meta-analysis

M. Kraemer, J. Jansen, G. Capkun-Niggli, 2012, International journal of chronic obstructive pulmonary disease.

Inhaled corticosteroids and the risk of pneumonia in Medicare patients with COPD

D. Goldman, Jie Zhang, Y. Luna, 2012, Current medical research and opinion.

Letter to Editor Regarding "Comparing Efficacy, Safety, and Pre-Infusion Period of Axicabtagene Ciloleucel vs Tisagenlecleucel in Relapsed/Refractory Large B-Cell Lymphoma".

Junlong Li, E. Wu, J. Signorovitch, 2020, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Patterns of resource utilization and cost for postmenopausal women with hormone-receptor–positive, human epidermal growth factor receptor-2–negative advanced breast cancer in Europe

P. Neven, F. André, G. Jerusalem, 2015, BMC Cancer.

Evaluating Expected Costs and Benefits of Granting Access to New Treatments on the Basis of Progression-Free Survival in Non-Small-Cell Lung Cancer.

D. Goldman, D. Lakdawalla, Jie Zhang, 2015, JAMA oncology.

The Economic Value of CTL019 Therapy for Pediatric Patients with Relapsed and Refractory Acute Lymphoblastic Leukemia in the United Kingdom

K. Batt, P. Karaca-Mandic, Y. Hao, 2017 .

Survival after stem-cell transplant in pediatric and young-adult patients with relapsed and refractory B-cell acute lymphoblastic leukemia

C. Keir, Jie Zhang, A. Crotta, 2018, Current medical research and opinion.

Brain metastases in patients with ALK+ non-small cell lung cancer: clinical symptoms, treatment patterns and economic burden

E. Wu, R. Nitulescu, K. Dea, 2015, Journal of medical economics.

Indirect Comparisons: A Brief History and a Practical Look Forward

J. Signorovitch, Jie Zhang, 2017 .

Association between time to progression and subsequent survival inceritinib-treated patients with advanced ALK-positive non-small-cell lung cancer

Geoffrey Liu, Junlong Li, Zheng-Yi Zhou, 2016, Current medical research and opinion.

Impact of omalizumab on emergency-department visits, hospitalizations, and corticosteroid use among patients with uncontrolled asthma.

M. Duh, P. Lefebvre, Jie Zhang, 2012, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

Characteristics, treatment patterns, and survival among ALK+ non-small cell lung cancer (NSCLC) patients treated with crizotinib: A chart review study.

Keunchil Park, O. Arrieta, E. Swallow, 2016, Lung cancer.

P. Neven, M. Piccart, G. Hortobagyi, 2013, Current medical research and opinion.

Burden of illness of patients with allergic asthma versus non-allergic asthma

P. Lefebvre, Jie Zhang, M. Lafeuille, 2013, The Journal of asthma : official journal of the Association for the Care of Asthma.

Cost of adverse events during treatment with everolimus plus exemestane or single-agent chemotherapy in patients with advanced breast cancer in Western Europe

M. Campone, J. Signorovitch, Hongbo Yang, 2014, Journal of medical economics.

The value of surrogate endpoints for predicting real-world survival across five cancer types

R. Brookmeyer, R. Figlin, J. Shafrin, 2016, Current medical research and opinion.

Comparative Efficacy of Ceritinib and Crizotinib as Initial ALK–Targeted Therapies in Previously Treated Advanced NSCLC: An Adjusted Comparison with External Controls

Geoffrey Liu, Zheng-Yi Zhou, J. Signorovitch, 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.